* Edwards Lifesciences Corp EW.N EW is expected to show
a rise
in quarterly revenue when it reports results on October 24 for
the period ending September 30 2024
* The Irvine California-based company is expected to report
a
2.7% increase in revenue to $1.522 billion from $1.48 billion a
year ago, according to the mean estimate from 23 analysts, based
on LSEG data.The company's guidance on July 24 2024, for the
period ended September 30, was for revenue between $1.56 billion
and $1.64 billion.
* LSEG's mean analyst estimate for Edwards Lifesciences
Corp is
for earnings of 64 cents per share. The company's EPS guidance
on July 24 2024, for the period ended September 30, was between
$0.67 and $0.71
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 18
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Edwards
Lifesciences Corp is 75.00, above its last closing price
of $69.24.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 0.70 0.69 0.70 Beat 0.9
Mar. 31 2024 0.64 0.64 0.66 Beat 2.7
Dec. 31 2023 0.64 0.64 0.64 Met 0.4
Sep. 30 2023 0.59 0.59 0.59 Met -0.4
Jun. 0.65 0.65 0.66 Beat 2
30 2023
Mar. 31 2023 0.61 0.61 0.62 Beat 2.1
Dec. 31 2022 0.62 0.61 0.64 Beat 4.5
Sep. 30 2022 0.63 0.62 0.61 Missed -2
This summary was machine generated October 23 at 03:54 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)